Key result
Circulating microRNAs offer potential as epigenetic biomarkers for differentiating heart failure subtypes (HFrEF and HFpEF) and providing diagnostic and prognostic insights.
Why the study?
Heart failure subtypes HFpEF and HFrEF share similar clinical syndromes but differ in mortality and therapeutic response, motivating an exploration of whether distinct circulating microRNA profiles can provide diagnostic or prognostic utility.
Do circulating microRNAs have diagnostic and prognostic value in differentiating heart failure subtypes (HFrEF and HFpEF)?
Design
Review
Authors
Loading...
May support microRNA profiling in HF subtyping; leaves open need for prospective validation before clinical use.
Do circulating microRNAs have diagnostic and prognostic value in differentiating heart failure subtypes (HFrEF and HFpEF)?
Circulating microRNAs may serve as valuable diagnostic and prognostic biomarkers to differentiate between heart failure subtypes such as HFrEF and HFpEF.
Chen et al. (2019) conducted a review in Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF). Circulating microRNAs was evaluated. Circulating microRNAs offer potential as epigenetic biomarkers for differentiating heart failure subtypes (HFrEF and HFpEF) and providing diagnostic and prognostic insights.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: